Author:
Guzek A.,Korzeniewski K.,Nitsch-Osuch Aneta,Rybicki Z.,Prokop E.
Reference22 articles.
1. Chastre, J., Wunderink, R., Prokocimer, P., Lee, M., Kaniga, K., & Friedland, I. (2008). Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Critical Care Medicine, 36, 1089–1096.
2. Clinical and Laboratory Standards Institute. (2008). Performance standards for antimicrobial susceptibility testing; M100-S18, 18th informational supplement (CLSI). Wayne: Clinical and Laboratory Standards Institute.
3. Food and Drug Administration (2011). FDA criteria. http://www.fda.gov . Accessed on 12 Aug 2011.
4. Hanberger, A., Arman, D., Gill, H., Jindrák, V., Kalenic, S., Kurcz, A., Licker, M., Naaber, P., Scicluna, E. A., Vanis, V., & Walther, S. M. (2009). Surveillance of microbial in European Intensive Care Units: A first report from the Care-ICU programme for improved infection control. Intensive Care Medicine, 35, 91–100.
5. Hoban, D. J., Jones, R. N., Yamane, N., Frei, R., Trilla, A., & Pignatari, A. C. (1993). In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagnostic Microbiology and Infectious Disease, 17, 299–305.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献